Current developments of gene therapy in human diseases

被引:2
作者
Liu, Fanfei [1 ]
Li, Ruiting [2 ]
Zhu, Zilin [3 ]
Yang, Yang [1 ,2 ]
Lu, Fang [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China
[3] Sichuan Univ, Coll Life Sci, Chengdu, Sichuan, Peoples R China
来源
MEDCOMM | 2024年 / 5卷 / 09期
基金
中国国家自然科学基金;
关键词
AAV; clinical trials; CRISPR-Cas; gene therapy; human diseases; DUCHENNE MUSCULAR-DYSTROPHY; MACULAR DEGENERATION; OPEN-LABEL; PARKINSONS-DISEASE; IN-VIVO; VORETIGENE NEPARVOVEC; AUREUS CRISPR-CAS9; IMMUNE-RESPONSES; RECOMBINANT AAV; HEART-FAILURE;
D O I
10.1002/mco2.645
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Gene therapy has witnessed substantial advancements in recent years, becoming a constructive tactic for treating various human diseases. This review presents a comprehensive overview of these developments, with a focus on their diverse applications in different disease contexts. It explores the evolution of gene delivery systems, encompassing viral (like adeno-associated virus; AAV) and nonviral approaches, and evaluates their inherent strengths and limitations. Moreover, the review delves into the progress made in targeting specific tissues and cell types, spanning the eye, liver, muscles, and central nervous system, among others, using these gene technologies. This targeted approach is crucial in addressing a broad spectrum of genetic disorders, such as inherited lysosomal storage diseases, neurodegenerative disorders, and cardiovascular diseases. Recent clinical trials and successful outcomes in gene therapy, particularly those involving AAV and the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated proteins, are highlighted, illuminating the transformative potentials of this approach in disease treatment. The review summarizes the current status of gene therapy, its prospects, and its capacity to significantly ameliorate patient outcomes and quality of life. By offering comprehensive analysis, this review provides invaluable insights for researchers, clinicians, and stakeholders, enriching the ongoing discourse on the trajectory of disease treatment. Gene therapy has seen remarkable advancements in recent decades, demonstrating its immense potential in treating a wide range of genetic and acquired diseases. Several AAV gene therapy products have been introduced to the market, addressing various conditions. This review explores the clinical applications of AAV in major human diseases, including ocular diseases, neuromuscular diseases, hematological diseases, neurological diseases, cardiovascular diseases, and lysosomal storage diseases. image
引用
收藏
页数:30
相关论文
共 215 条
  • [21] Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study
    Campochiaro, Peter A.
    Lauer, Andreas K.
    Sohn, Elliott H.
    Mir, Tahreem A.
    Naylor, Stuart
    Anderton, Matthew C.
    Kelleher, Michelle
    Harrop, Richard
    Ellis, Scott
    Mitrophanous, Kyriacos A.
    [J]. HUMAN GENE THERAPY, 2017, 28 (01) : 99 - 111
  • [22] Indirect Comparison of Lenadogene Nolparvovec Gene Therapy Versus Natural History in Patients with Leber Hereditary Optic Neuropathy Carrying the m.11778G>A MT-ND4 Mutation
    Carelli, Valerio
    Newman, Nancy J.
    Yu-Wai-Man, Patrick
    Biousse, Valerie
    Moster, Mark L.
    Subramanian, Prem S.
    Vignal-Clermont, Catherine
    Wang, An-Guor
    Donahue, Sean P.
    Leroy, Bart P.
    Sergott, Robert C.
    Klopstock, Thomas
    Sadun, Alfredo A.
    Fernandez, Gema Rebolleda
    Chwalisz, Bart K.
    Banik, Rudrani
    Girmens, Jean Francois
    La Morgia, Chiara
    DeBusk, Adam A.
    Jurkute, Neringa
    Priglinger, Claudia
    Karanjia, Rustum
    Josse, Constant
    Salzmann, Julie
    Montestruc, Francois
    Roux, Michel
    Taiel, Magali
    Sahel, Jose-Alain
    [J]. OPHTHALMOLOGY AND THERAPY, 2023, 12 (01) : 401 - 429
  • [23] Hemophilia A and B: molecular and clinical similarities and differences
    Castaman, Giancarlo
    Matino, Davide
    [J]. HAEMATOLOGICA, 2019, 104 (09) : 1702 - 1709
  • [24] Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR
    Cehajic-Kapetanovic, Jasmina
    Xue, Kanmin
    Martinez-Fernandez de la Camara, Cristina
    Nanda, Anika
    Davies, Alexandra
    Wood, Laura J.
    Salvetti, Anna Paola
    Fischer, M. Dominik
    Aylward, James W.
    Barnard, Alun R.
    Jolly, Jasleen K.
    Luo, Edmond
    Lujan, Brandon J.
    Ong, Tuyen
    Girach, Aniz
    Black, Graeme C. M.
    Gregori, Ninel Z.
    Davis, Janet L.
    Rosa, Potyra R.
    Lotery, Andrew J.
    Lam, Byron L.
    Stanga, Paulo E.
    MacLaren, Robert E.
    [J]. NATURE MEDICINE, 2020, 26 (03) : 354 - +
  • [25] Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration
    Chakravarthy, U.
    Adamis, A. P.
    Cunningham, E. T., Jr.
    Goldbaum, M.
    Guyer, D. R.
    Katz, B.
    Patel, Manju
    [J]. OPHTHALMOLOGY, 2006, 113 (09) : 1508 - 1521
  • [26] Inflammation in Viral Vector-Mediated Ocular Gene Therapy: A Review and Report From a Workshop Hosted by the Foundation Fighting Blindness, 9/2020
    Chan, Ying Kai
    Dick, Andrew D.
    Hall, Sara Mary
    Langmann, Thomas
    Scribner, Curtis L.
    Mansfield, Brian C.
    [J]. TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2021, 10 (04):
  • [27] Chang J, 2021, IMMUNE NETW, V21
  • [28] Enhanced prime editing systems by manipulating cellular determinants of editing outcomes
    Chen, Peter J.
    Hussmann, Jeffrey A.
    Yan, Jun
    Knipping, Friederike
    Ravisankar, Purnima
    Chen, Pin-Fang
    Chen, Cidi
    Nelson, James W.
    Newby, Gregory A.
    Sahin, Mustafa
    Osborn, Mark J.
    Weissman, Jonathan S.
    Adamson, Britt
    Liu, David R.
    [J]. CELL, 2021, 184 (22) : 5635 - +
  • [29] Excess cones in the retinal degeneration rd7 mouse, caused by the loss of function of orphan nuclear receptor Nr2e3, originate from early-born photoreceptor precursors
    Cheng, Hong
    Khan, Naheed W.
    Roger, Jerome E.
    Swaroop, Anand
    [J]. HUMAN MOLECULAR GENETICS, 2011, 20 (21) : 4102 - 4115
  • [30] Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial
    Chien, Yin-Hsiu
    Lee, Ni-Chung
    Tseng, Sheng-Hong
    Tai, Chun-Hwei
    Muramatsu, Shin-ichi
    Byrne, Barry J.
    Hwu, Wuh-Liang
    [J]. LANCET CHILD & ADOLESCENT HEALTH, 2017, 1 (04) : 265 - 273